Q1 FY27 results: Sales up 20%, standalone PAT at Rs 5.05 cr

Results View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.7%Reaction day

₹190.54

prior close

₹181.66

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.7% vs market

Pharmaceuticals peers, median of 166sector-0.4%-4.3% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.7+0.1-4.7-0.4-4.3

Next day

-9.4+0.2-9.6-0.3-9.1

-13.9+0.6-14.5-0.5-13.4

-17.1-0.0-17.1-1.3-15.8

-14.7+0.5-15.2-0.8-13.9

-14.5+0.8-15.3-0.4-14.1

-10.2+0.6-10.8-0.9-9.4

15d

-5.0+1.3-6.3+0.0-5.1

+0.2-1.4+1.6-0.1+0.3

+20.7-0.6+21.2-2.8+23.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kilitch Drugs posted Q1 FY27 standalone net sales of Rs 40.91 cr, up about 20% YoY from Rs 34.12 cr. Standalone PAT rose modestly to Rs 5.05 cr vs Rs 4.79 cr. However, consolidated PAT dipped to Rs 1.97 cr from Rs 2.26 cr, dragged by losses at foreign subsidiary Kilitch Estro Biotech PLC (loss of about Rs 2.87 cr). Standalone EPS at Rs 1.45. Auditor gave an unqualified limited review report.

Likely market impact

Mixed bag - strong standalone growth but consolidated hit by subsidiary losses. Worth watching foreign subsidiary recovery.